HC Wainwright Boosts Vera Therapeutics (NASDAQ:VERA) Price Target to $85.00

Vera Therapeutics (NASDAQ:VERA - Get Free Report) had its target price upped by equities researchers at HC Wainwright from $75.00 to $85.00 in a research note issued on Monday,Benzinga reports. The firm presently has a "buy" rating on the stock. HC Wainwright's price target would suggest a potential upside of 174.99% from the stock's current price.

Other research analysts have also issued reports about the company. Wolfe Research initiated coverage on Vera Therapeutics in a research report on Tuesday, February 4th. They issued an "outperform" rating and a $49.00 price objective on the stock. JPMorgan Chase & Co. lowered their target price on Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating for the company in a report on Tuesday, March 4th. Cantor Fitzgerald lowered their target price on Vera Therapeutics from $107.00 to $100.00 and set an "overweight" rating for the company in a report on Wednesday, May 7th. Guggenheim upped their target price on Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a report on Thursday, February 27th. Finally, Wedbush reduced their price objective on Vera Therapeutics from $34.00 to $26.00 and set a "neutral" rating for the company in a research report on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $65.00.

Vera Therapeutics Stock Performance

Shares of VERA stock traded down $0.83 during trading hours on Monday, reaching $30.91. 4,851,826 shares of the company's stock were exchanged, compared to its average volume of 860,948. The company has a market cap of $1.97 billion, a P/E ratio of -11.84 and a beta of 1.28. The company's 50 day moving average is $22.06 and its two-hundred day moving average is $31.86. Vera Therapeutics has a 1 year low of $18.53 and a 1 year high of $51.61. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.81) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). During the same quarter in the previous year, the business posted ($0.56) earnings per share. Equities research analysts anticipate that Vera Therapeutics will post -2.89 EPS for the current fiscal year.

Institutional Trading of Vera Therapeutics

Hedge funds have recently modified their holdings of the business. Huntington National Bank purchased a new stake in shares of Vera Therapeutics in the fourth quarter valued at $26,000. AlphaQuest LLC acquired a new position in shares of Vera Therapeutics in the fourth quarter worth $34,000. GF Fund Management CO. LTD. acquired a new position in shares of Vera Therapeutics in the fourth quarter worth $56,000. Quarry LP increased its stake in shares of Vera Therapeutics by 25.0% in the first quarter. Quarry LP now owns 2,500 shares of the company's stock worth $60,000 after acquiring an additional 500 shares during the last quarter. Finally, KBC Group NV increased its stake in shares of Vera Therapeutics by 127.2% in the fourth quarter. KBC Group NV now owns 2,477 shares of the company's stock worth $105,000 after acquiring an additional 1,387 shares during the last quarter. Hedge funds and other institutional investors own 99.21% of the company's stock.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.